10th Jan 2017 08:26
LONDON (Alliance News) - Hutchison China MediTech Ltd on Tuesday said it has started a phase one trial of its HMPL-523 spleen tyrosine kinase inhibitor in China.
The drug is being trialled on patients with hematological malignancies in China. The first patient was dosed in late December.
The study will complement the ongoing phase one trial in patients in Australia with hematological malignancies, which is expected to complete dose-escalation in the first half of 2017.
Hutchison China shares were up 0.3% at 2,300.00 pence on Tuesday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2017 Alliance News Limited. All Rights Reserved.
Related Shares:
Hutchmed